A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| BMS-986142 | BMS-986142 is a potent and highly selective reversible inhibitor of Bruton's tyrosine kinase (BTK) with an IC50 of 0.5 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 1643368-58-4. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-101856. |  |
| BMS-986142 | Bruton's tyrosine kinase (BTK) is a nonreceptor tyrosine kinase. It is a member of the Tec family of kinases. BTK plays an essential role in B cell receptor (BCR)-mediated signaling as well as Fcγ receptor signaling in monocytes and Fcε receptor signaling. BMS-986142 is a potent, selective and reversible BTK inhibitor with IC50 of 0.5 nM. It potently inhibits BCR-stimulated expression of CD69 on B cells in human whole blood with IC50 of 90 nM. Synonyms: BMS-986142; BMS986142. Grade: ≥98%. CAS No. 1643368-58-4. Molecular formula: C32H30F2N4O4. Mole weight: 572.60. |  |
| BMS-986143 | BMS-986143 is an orally active, reversible BTK inhibitor with an IC50 of 0.26 nM. BMS-986143 also inhibits TEC, BLK, BMX, TXK FGR, YES1 and ITK with IC50s of 3 nM, 5 nM, 7 nM, 10 nM, 15 nM, 19 nM and 21 nM, respectively. BMS-986143 can be used in the study of autoimmune diseases. Synonyms: 3-chloro-4-(3-(5-chloro-1,3-dioxo-1H-pyrido[1,2-c]pyrimidin-2(3H)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9H-carbazole-1-carboxamide; 9H-Carbazole-1-carboxamide, 3-chloro-4-[3-(5-chloro-1,3-dioxo-1H-pyrido[1,2-c]pyrimidin-2(3H)-yl)-2-methylphenyl]-7-(1-hydroxy-1-methylethyl)-. Grade: ≥98%. CAS No. 1643372-95-5. Molecular formula: C31H24Cl2N4O4. Mole weight: 587.45. | |
| BMS-986158 | BMS-986158 is an inhibitor of the bromodomain and extra-terminal (BET) proteins with potential antineoplastic activity. Synonyms: 2-[3-(3,5-dimethyltriazol-4-yl)-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-7-yl]propan-2-ol; BMS-986158; BMS 986158; BMS986158. CAS No. 1800340-40-2. Molecular formula: C30H33N5O2. Mole weight: 495.62. | |
| BMS-986158 | BMS-986158 is a potent BET inhibitor with IC50s of 6.6 and 5 nM in NCI-H211 small cell lung cancer (SCLC) cells and MDA-MB231 triple negative breast cancer (TNBC) cells, respectively[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1800340-40-2. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-101567. | |
| BMS-986165 | BMS-986165 is a potent and selective TYK2 inhibitor that blocks signal transduction of IL-23, IL-12, and type I IFNs. It binds to the Tyk2 pseudokinase domain (Ki = 0.02 nM), and is highly selective against a panel of 265 kinases and pseudokinases. BMS-986165 is under a phase III clinical trial for the treatment of Psoriasis. Synonyms: Deucravacitinib; BMS 986165; BMS986165; Tyk2-IN-4; Sotyktu. Grade: 98%. CAS No. 1609392-27-9. Molecular formula: C20H19D3N8O3. Mole weight: 425.47. | |
| BMS-986165 (Deucravacitinib) | Deucravacitinib (BMS-986165) is a highly potent and selective allosteric inhibitor of Tyk2 with a Ki value of 0.02 nM for binding to the Tyk2 pseudokinase domain. It is highly selective against a panel of 265 kinases and pseudokinases. Group: Inhibitors. CAS No. 1609392-27-9. Pack Sizes: 2mg. Product ID: S8879. Formula: C20H19D3N8O3. Smiles: CNC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4. Storage Conditions: 3 years -20°C powder. |  United States; Europe |
| BMS-986176 | BMS-986176 (LX-9211) is a highly selective, brain-penetrant, potent AAK1 (adaptor associated kinase 1) inhibitor with an IC50 of 2 nM. BMS-986176 can be used for neurodegenerative diseases research[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: LX-9211; AAK1-IN-1. CAS No. 1815613-42-3. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-134829. | |
| BMS 986187 | BMS 986187 is a potent and selective δ-opioid receptor positive allosteric modulator (EC50 = 30 nM) exhibiting 100-fold selectivity for δ over μ-opioid receptor. Synonyms: BMS 986187; BMS986187; BMS-986187; 3,4,5,6,7,9-Hexahydro-3,3,6,6-tetramethyl-9-[4-[(2-methylphenyl)methoxy]phenyl]-1H-xanthene-1,8(2H)-dione. Grade: ≥98% by HPLC. CAS No. 684238-37-7. Molecular formula: C31H34O4. Mole weight: 470.61. | |
| BMS 986188 | BMS 986188 is a novel potent and selective positive allosteric modulator of the delta-opioid receptor. It is selective for δ- over μ-opioid receptors with EC50 of 10 μM in the presence of leu-enkephalin and the μ-opioid receptor agonist endomorphin 1, respectively. Synonyms: MS-986188; BMS 986188. Grade: ≥98%. CAS No. 1776115-10-6. Molecular formula: C30H31BrO4. Mole weight: 535.5. | |
| BMS-986189 | BMS-986189 is a macrocyclic peptide PD-1/PD-L1 interaction with an IC50 of 1.03 nM inhibitor. BMS-986189 can be used for cancer research, such as human lung carcinoma cells L2987[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1629665-96-8. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-P10375. | |
| BMS-986195 | BMS-986195 is a Bruton's tyrosine kinase (BTK) inhibitor with IC50 of 0.1 nM. Synonyms: Branebrutinib; BMS 986195; BMS986195. Grade: ≥98% by HPLC. CAS No. 1912445-55-6. Molecular formula: C20H23FN4O2. Mole weight: 370.42. | |
| BMS986195 R-isomer | An R isomer of BMS-986195, a potent and selective inhibitor of Bruton's tyrosine kinase (BTK). Synonyms: (R)-4-(3-(But-2-ynamido)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; (R)-Branebrutinib; (R)-BMS-986195. CAS No. 1912445-70-5. Molecular formula: C20H23FN4O2. Mole weight: 370.42. | |
| BMS-986202 | BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC50 value of 0.19 nM and a Ki of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC50 value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1771691-34-9. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-131968. | |
| BMS-986205 | BMS-986205 is a selective indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor. It is undergoing a phase I/II clinical trial for the bladder and cervical cancer therapy in combination with nivolumab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody. Uses: Drug combination with nivolumab. Synonyms: BMS-986205; BMS 986205; BMS986205; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide. CAS No. 1923833-60-6. Molecular formula: C24H24ClFN2O. Mole weight: 410.917. | |
| BMS-986224 | BMS-986224 is a potent, selective and orally active APJ receptor agonist (Kd = 0.3 nM). BMS-986224 exhibits similar receptor binding and signaling profile to (Pyr1) apelin-13. BMS-986224 has the potential for the research of heart failure[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2055200-88-7. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-139485. | |
| BMS-986235 | BMS-986235 (LAR-1219) is a selective, orally active formyl peptide receptor 2 (FPR2) agonist, with EC50s of 0.41 nM and 3.4 nM for hFPR2 and mFPR2, respectively. BMS-986235 has potential for the prevention of heart failure[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: LAR-1219. CAS No. 2253947-47-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 250 mg; 500 mg; 1 g. Product ID: HY-131180. | |
| BMS-986238 | BMS-986238 is an orally active macrocyclic peptide PD-L1 inhibitor. BMS-986238 can be used in the research of tumors such as solid tumors and lymphomas[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2919596-13-5. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-172320. | |
| BMS-986242 | BMS-986242 is a potent and selective inhibitor of Indoleamine 2,3-dioxygenase 1 (IDO1), a heme-containing dioxygenase enzyme implicated in cancer immune response. BMS-986242 has been developed for the treatment of a variety of cancers including metastatic melanoma and renal cell carcinoma. Synonyms: BMS 986242; BMS986242. Grade: 98% by HPLC. CAS No. 1923844-48-7. Molecular formula: C24H24ClFN2O. Mole weight: 410.9. | |
| BMS-986260 | BMS-986260, an immuno-oncology agent, is a potent, selective, and orally active TGFβR1 inhibitor (IC50=1.6 nM). BMS-986260 displays exquisite selectivity for TGFβR1 over its isozyme TGFβR2, as well as in a panel of more than 200 kinases examined. BMS-986260 inhibits TGFβ mediated nuclear translocation of pSMAD2/3 in MINK and NHLF cells lines with an IC50 of 350 nM and 190 nM, respectively[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2001559-19-7. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg. Product ID: HY-W107024. | |
| BMS-986278 | BMS-986278 is a potent and orally active lysophosphatidic acid receptor 1 (LPA1) antagonist, with Kbs of 6.9 nM and 4.0 nM for human and mouse LPA1, respectively. BMS-986278 can be used for the research of pulmonary fibrotic diseases[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: Admilparant. CAS No. 2170126-74-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 1 g. Product ID: HY-139853. | |
| BMS-986278 | BMS-986278 is a potent antagonist of lysophosphatidic acid receptor 1 (LPA1), with a human LPA1 Kb of 6.9 nM. Synonyms: (1S,3S)-3-((2-Methyl-6-(1-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)oxy)cyclohexane-1-carboxylic acid; Cyclohexanecarboxylic acid, 3-((2-methyl-6-(1-methyl-5-((((methylpropylamino)carbonyl)oxy)methyl)-1H-1,2,3-triazol-4-yl)-3-pyridinyl)oxy)-, (1S,3S)-. Grade: ≥95%. CAS No. 2170126-74-4. Molecular formula: C22H31N5O5. Mole weight: 445.51. | |
| BMS-986299 | BMS-986299 is a first-in-class NLRP3 inflammasome agonist with EC50 of 1.28 μM. BMS-986299 is usdergoing a clinical trial alone and in combination with Nivolumab and Ipilimumab for the treatment of advanced solid tumors. Synonyms: BMS 986299; BMS986299. CAS No. 2242952-69-6. Molecular formula: C18H19N7O. Mole weight: 349.39. | |
| BMS-986299 | BMS-986299 (compound 112) is a first-in-class NLRP3 inflammasome agonist with an EC50 of 1.28 μM. (patent WO2018152396A1). Uses: Scientific research. Category: Signaling pathways. CAS No. 2242952-69-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-139396. | |
| BMS-986365 | BMS-986365 (CC-94676) is an orally active and selective targeted androgen receptor (AR) PROTAC degrader (DC50 of 10-40 nM). BMS-986365 is capable of inducing cereblon (CRBN) E3 ligase-dependent ubiquitination and degradation of the androgen receptor (AR), as well as various AR mutants. BMS-986365 shows no degradation of the close AR family members estrogen receptor (ER), progesterone receptor (PR), and glucocorticoid receptor (GR). BMS-986365 shows significant in vivo potency, degrading AR, inhibiting AR signaling, and restricting tumor growth in animal models of advanced prostate cancer. BMS-986365 can be used for the study of metastatic castration-resistant prostate cancer (mCRPC)[1][2][3][4]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: CC-94676. CAS No. 2446928-30-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 250 mg; 500 mg; 1 g. Product ID: HY-158101. | |
| BMS-986397 | BMS-986397 is a potent, selective, and orally active cereblon-based molecular glue degrader of casein kinase 1α (CK1α). BMS-986397 induces apoptosis and cell cycle arrest in acute myeloid leukemia (AML) cells. BMS-986397 is a promising agent for the investigation of AML and high-risk myelodysplastic syndromes (HR-MDS)[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2564486-44-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 250 mg; 500 mg; 1 g. Product ID: HY-159646. | |
| BMS-986408 | BMS-986408 is an orally active inhibitor of DGKα and DGKζ, with IC50 values of 0.0003 μM and 0.002 μM, respectively. BMS-986408 activates intratumoral T cell responses, enhances the priming and expansion of tumor-reactive T cells in tumor-draining lymph nodes, and functions as an immunostimulant. BMS-986408 can be used in the research of tumors[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2618418-12-3. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-159649. | |
| BMS-986458 | BMS-986458 is a highly selective, orally active cereblon-based BCL6 PROTAC degrader and antitumor agent. BMS-986458 selectively degrades BCL6 by binding cereblon to the BTB domain of BCL6, thereby regulating the cell cycle, antiproliferative and interferon signaling pathways, and upregulating the expression and distribution of CD20. BMS-986458 modulates the phenotype of follicular helper T cells and reduces circulating tumor DNA levels. The combination of BMS-986458 with CD20xCD3 bispecific antibody also enhances the efficiency of T cell tumor infiltration and expansion. BMS-986458 induces regression of BCL6-positive tumors and prolongs survival, and it is suitable for research related to B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, and relapsed/refractory lymphoma[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3005272-36-3. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-172736. | |
| BMS-986463 | BMS-986463, a CRBN E3 ligase modulator (CELMoD), is a WEE1 kinase molecular glue degrader. BMS-986463 significantly inhibits tumor regression and reduces the level of phospho-CDK2. BMS-986463 can be used for advanced malignant solid tumors like non-small cell lung cancer (NSCLC) research[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3025467-07-3. Pack Sizes: 1 mg; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-175749. | |
| BMS-986470 | BMS-986470, a HbF-activating CRBN E3 ligase modulator (CELMoD), is an orally active dual molecular glue degrader targeting ZBTB7A and WIZ. BMS-986470 has potent γ-globin induction activity. BMS-986470 can be used for sickle cell disease (SCD) research[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3036554-12-5. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-175742. | |
| BMS CCR2 22 | BMS CCR2 22 is a potent, specific and high affinity CC-type chemokine receptor 2 (CCR2) antagonist with excellent binding affinity (binding IC50 of 5.1 nM) and potent functional antagonism (calcium flux IC50 of 18 nM and chemotaxis IC50 of 1 nM)[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 445479-97-0. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-101908. | |
| BMS CCR2 22 | BMS CCR2 22. Group: Biochemicals. Grades: Purified. CAS No. 445479-97-0. Pack Sizes: 1mg, 10mg, 50mg. US Biological Life Sciences. |  Worldwide |
| BMS CCR2 22 | BMS CCR2 22 is a potent CCR2 antagonist. Synonyms: N-[2-[[2-[(4-methylsulfanylbenzoyl)amino]cyclohexyl]amino]-2-oxoethyl]-2-(propan-2-ylcarbamoylamino)-5-(trifluoromethyl)benzamide. CAS No. 445479-97-0. Molecular formula: C28H34F3N5O4S. Mole weight: 593.66. | |
| BMS-P5 | BMS-P5 is a novel peptidylarginine deiminase 4 (PAD4) inhibitor with pIC50 values in the range of 5-7.5. BMS-P5 blocks MM-induced NET formation and delays progression of MM in a syngeneic mouse model. Synonyms: BM P5; BMSP5; BMSP-5; BMSP 5; BMS-P5 HCl. CAS No. 1549811-36-0. Molecular formula: C27H33ClN6O2. Mole weight: 509.04. | |
| BMS-P5 free base | BMS-P5 is a novel peptidylarginine deiminase 4 (PAD4) inhibitor with pIC50 values in the range of 5-7.5. BMS-P5 blocks MM-induced NET formation and delays progression of MM in a syngeneic mouse model. Synonyms: [(2S,5R)-5-amino-2-methyl-1-piperidinyl][2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-methanone. Grade: 99%. CAS No. 1550371-22-6. Molecular formula: C27H32N6O2. Mole weight: 472.59. | |
| BMSpep-57 | BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1629655-80-6. Pack Sizes: 1 mg; 5 mg. Product ID: HY-P3143. | |
| BMSpep-57 | BMSpep-57 is a potent and competitive PD-1/PD-L1 interaction macrocyclic peptide inhibitor. Synonyms: BMSpep-57; SCHEMBL17810340; HY-P3143; AKOS040756947; 1629655-80-6; CS-0149181. CAS No. 1629655-80-6. Molecular formula: C89H126N24O19S. Mole weight: 1868.16. | |
| BMT-090605 hydrochloride | BMT-090605 hydrochloride is a potent, selective the adapter protein-2 associated kinase 1 (AAK1) inhibitor with an IC50 value of 0.6 nM. BMT-090605 hydrochloride shows antinociceptive activity. BMT-090605 hydrochloride inhibits BMP-2-inducible protein kinase (BIKE) and Cyclin G-associated kinase (GAK) with IC50 values of 45 nM and 60 nM, respectively. BMT-090605 hydrochloride can be used for the research of neuropathic pain[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2231664-45-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-101290A. | |
| BMT-1438 | BMT-1438 is a selective inhibitor of Janus kinase (JAK) family with less side effcts which is potentially used for the treatment of rheumatoid arthritis and other autoimmune diseases. It has a preference for JAK1 and JAK3. BMT-1438 showed excellent effect both in vitro and in a collagen-induced arthritis mouse model. Uses: The potential treatment of rheumatoid arthritis and other autoimmune diseases. Synonyms: BMT-1438; BMT 1438; BMT1438. | |
| BMT-145027 | BMT-145027 is a potent mGluR5 PAM without inherent agonist activity with an EC50 of 47 nM. BMT-145027 is a non-MPEP site PAM to demonstrate in vivo efficacy. Synonyms: BMT-145027; BMT 145027; BMT145027; 3-[4-chloro-3-(trifluoromethyl)phenyl]-4-cyclopropyl-6-phenyl-2H-pyrazolo[3,4-b]pyridine-5-carbonitrile. CAS No. 2018282-44-3. Molecular formula: C23H14ClF3N4. Mole weight: 438.83. | |
| Bmt I | One unit of the enzyme is the amount required to hydrolyze 1 μg of Lambda DNA (Hind III-digest) in 1 hour at 37°C in a total reaction volume of 50 μl. Applications: After 20-fold overdigestion with enzyme about 95% of the dna fragments can be ligated and recut. Group: Restriction Enzymes. Purity: 1000U; 5000U. GCTAG↑C C↓GATCG. Activity: 20000u.a./ml. Appearance: 10 X SE-buffer W. Storage: -20°C. Form: Liquid. Source: An E.coli strain that carries the cloned Bmt I gene from Bacillus megaterium S2. Pack: 10 mM Tris-HCl (pH 7.5); 200 mM NaCl; 0.1 mM EDTA; 1 mM DTT; 200 μg/ml BSA; 50% glycerol. Cat No: ET-1036RE. |  |
| Bmu I | One unit of the enzyme is the amount required to hydrolyze 1 μg of Lambda DNA (HindIII-digest) in 1 hour at 37°C in a total reaction volume of 50 μl. Applications: After 2-fold overdigestion with enzyme about 75% of the dna fragments can be ligated and 95% may be recut. Group: Restriction Enzymes. Purity: 50U; 250U. ACTGGG(N)5↑ TGACCC(N)4&darr. Activity: 500-1000u.a./ml. Appearance: 10 X SE-buffer Y. Storage: -20°C. Form: Liquid. Source: Bacillus megaterium S87. Pack: 10 mM Tris-HCl (pH 7.5); 250 mM NaCl; 0.1 mM EDTA; 7 mM 2-mercaptoethanol; 50% glycerol. Cat No: ET-1037RE. | |
| BMVC | BMVC is the first fluorescent probe designed to detect G-quadruplexes (G4s) in vivo. BMVC is a potent G-quadruplex (G4) stabilizer and a selective telomerase inhibitor. Grade: 98%. CAS No. 627810-06-4. Molecular formula: C28H25I2N3. Mole weight: 657.33. | |
| BMVC2 | BMVC2, a bisubstituted carbazole derivative of BMVC, is a G-quadruplex (G4) stabilizer. Synonyms: o-BMVC; 2,2'-((9H-Carbazole-3,6-diyl)bis(ethene-2,1-diyl))bis(1-methylpyridin-1-ium) iodide; 2,2'-[9H-Carbazole-3,6-diyldi(E)-2,1-ethenediyl]bis(1-methylpyridinium) diiodide. Grade: ≥95%. CAS No. 850559-51-2. Molecular formula: C28H25I2N3. Mole weight: 657.33. | |
| BMV Gag-(7-25) | It is a cell penetrating peptide. Synonyms: H-Lys-Met-Thr-Arg-Ala-Gln-Arg-Arg-Ala-Ala-Ala-Arg-Arg-Asn-Arg-Trp-Thr-Ala-Arg-OH; L-lysyl-L-methionyl-L-threonyl-L-arginyl-L-alanyl-L-glutaminyl-L-arginyl-L-arginyl-L-alanyl-L-alanyl-L-alanyl-L-arginyl-L-arginyl-L-asparagyl-L-arginyl-L-tryptophyl-L-threonyl-L-alanyl-L-arginine. Grade: ≥95%. Molecular formula: C96H170N44O24S. Mole weight: 2356.76. | |
| BMX-IN-1 | A cell-permeable tricyclic quinoline-acrylamide compound that potently inhibits BMX and BTK kinase activity (IC50 = 8 and 10.4nM, respectively) by covalently targeting ATP-binding site cysteine, while being less potent against TEC family kinases TEC, JAK3, BLK with the same conserved cysteine (IC50 = 175, 377, and 653nM, respectively). Only PI 3-K gamma/PIK3CG, SBK1, PIP5K2C (by ≥94% at 1uM), and TXK (by 75% at 1uM) are significantly inhibited by BMX-IN-1 in a selectivity profiling against 437 other kinase constructs. Potently inhibits the proliferation of TEL-BMX transformed Ba/F3 Ba/F3 (GI50 = 25nM), while being much less effective against TEL-BLK, TEL-JAK1, TEL-JAK2, TEL-JAK3, or TEL-TYK2E957D transformed Ba/F3 (GI50 = ≥3.64uM) or a panel of 5 prostate cancer cell lines (GI50 ≥2.46uM). Group: Biochemicals. Alternative Names: N- (2-Methyl-5- (9- (4- (methylsulfonamido) phenyl) -2-oxobenzo[h][1, 6]naphthyridin-1 (2H) -yl) phenyl) acrylamide, BMX/BTK Inhibitor, Bruton's Tyrosine Kinase Inhibitor IV, BLK Inhibitor I, BMX Inhibitor I, JAK3 Inhibitor XIII, PI 3-K Inhibitor XX, PIP5K2C Inhibitor I, SBK1 Inhibitor I, TEC Inhibitor I, TXK Inhibitor I. Grades: Highly Purified. CAS No. 1431525-23-4. Pack Sizes: 10mg. Molecular Formula: C??H??N?O?S. US Biological Life Sciences. | Worldwide |
| BMX-IN-1 | BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys496 in the BMX ATP binding domain with an IC50 of 8 nM, also targets the related Brutons tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity. Uses: Scientific research. Category: Signaling pathways. Alternative Names: BMX kinase inhibitor. CAS No. 1431525-23-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-80002. | |
| BMX-IN-1 | BMX-IN-1 selectively and irreversibly inhibits BMX (IC50=8nM) that is significant for ischemia-mediated arteriogenesis and lymphangiogenesis regulation. It also inhibits the proliferation of RV-1 (GI50s=2.54μM), DU-145 (GI50s=4.38μM), PC-3 (GI50s=5.37nM). Synonyms: N-[5-[9-[4-(methanesulfonamido)phenyl]-2-oxobenzo[h][1,6]naphthyridin-1-yl]-2-methylphenyl]prop-2-enamideBMX-IN-1; BMX-IN1; BMX-IN 1.1431525-23-3GTPL9269SCHEMBL17052523BDBM102620CS-1295; HY-80002; W-6056; CS 1295; HY 80002; W 6056; CS1295; HY80002; W6056Example 1-14 [ WO2014063054]N-[5-[9-[4-(methanesulfonamido)phenyl]. CAS No. 1431525-23-3. Molecular formula: C29H24N4O4S. Mole weight: 524.59. | |
| Bmy 14802 hydrochloride | Bmy 14802 hydrochloride. Alternative Names: BMY 14802 hydrochloride;alpha-(4-Fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol hydrochloride. CAS No. 105565-55-7. Purity: >99 %. Product ID: ACM105565557. Molecular formula: C18H22F2N4O.HCl. Mole weight: 384.85. Alfa Chemistry - ISO 9001:32057 Certified. |  |
| BMY 14802 hydrochloride | BMY 14802 hydrochloride is a potent sigma receptor antagonist (IC50 = 112 nM) with weak affinity for 5-HT1A and α1 receptors. BMY 14802 is potentially used as an atypical antipsychotic agent for schizophrenia treatment. Uses: Potential atypical antipsychotic agent. Synonyms: BMY 14802 hydrochloride; BMS-181100 hydrochloride; BMY14802 hydrochloride; BMS181100 hydrochloride; BMY-14802 hydrochloride; BMS 181100 hydrochloride; BMY 14802 HCl; α-(4-Fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol hydrochloride. Grade: ≥98% by HPLC. CAS No. 105565-55-7. Molecular formula: C18H22F2N4O.HCl. Mole weight: 384.86. | |
| BMY-25271 | BMY-25271 is an antagonist of histamine H2 receptor. Synonyms: N-[2-[[[5-[(Dimethylamino)methyl]furan-2-yl]methyl]thio]ethyl]-1,2,5-thiadiazole-3,4-diamine 1-oxide; 1,2,5-Thiadiazole-3,4-diamine, N3-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-, 1-oxide. Grade: ≥95%. CAS No. 78441-82-4. Molecular formula: C12H19N5O2S2. Mole weight: 329.44. | |
| BMY-28160 | BMY-28160 is an ester peptide antibiotic produced by Bacillus circulans H913-B4. It has anti-gram-positive bacteria, negative bacteria, anaerobic bacteria and fungi activity. Synonyms: Polypeptin A, 2-L-valine-9-L-serine-. CAS No. 94593-78-9. Molecular formula: C53H90N12O12. Mole weight: 1087.35. | |
| BMY-28190 | BMY-28190 is an antiviral antibiotic produced by Streptoalloteichus hindustanus E46594, which is a complex composed of D-a.Z-diaminobutyric acid. It has weak anti-gram-positive and negative bacteria activity, but has a strong inhibitory effect on type 1 herpes simplex virus (HSV-1), with IC50 of 2.8 μg/mL. CAS No. 117153-91-0. Molecular formula: (C4H8N2O)n. | |
| Bmy 42393 | BMY-42393 is a selective platelet aggregation inhibitor. It is also a prostacyclin partial agonist that inhibited ADP, collagen and thrombin-induced platelet aggregation with IC50 value range from 0.3 to 2.0 mM. BMY-42393 can stimulate platelet adenylate cyclase with EC50 value of 25 nM. BMY 42393 can also inhibit thrombin-induced elevation of intracellular free calcium. Research for the treatment of Hyperlipidaemia was discontinued. Uses: Hyperlipidaemia. Synonyms: BMY-42393; BMY 42393; BMY42393. SCHEMBL675089; AC1L304B; CHEMBL117835; 2-[3-[2-(4,5-diphenyl-1,3-oxazol-2-yl)ethyl]phenoxy]acetic acid. Grade: 98%. CAS No. 136451-58-6. Molecular formula: C25H21NO4. Mole weight: 399.45. | |
| BMY-43748 | BMY-43748 is an antibacterial compound with great in vitro and in vivo antibacterial activity. CAS No. 132195-65-4. Molecular formula: C20H17F3N4O3. Mole weight: 418.37. | |
| BMY 45778 | BMY 45778 is a non-prostanoid prostacyclin mimetic that acts as a partial agonist of IP1 prostacyclin receptors. It inhibits platelet aggregation in vitro (IC50 = 27-35 nM). Synonyms: BMY 45778; BMY45778; BMY-45778. [3-(4,5-Diphenyl[2,4'-bioxazol]-5'-yl)phenoxy]acetic acid. Grade: ≥99% by HPLC. CAS No. 152575-66-1. Molecular formula: C26H18N2O5. Mole weight: 438.44. | |
| BMY 7378 | BMY 7378 is a multi-targeted inhibitor of α2C-adrenoceptor and α1D-adrenoceptor with pKi of 6.54 and 8.2, respectively, and acts as a mixed agonist and antagonist for 5-HT1A receptor with pKi of 8.3. Uses: Adrenergic alpha-antagonists. Synonyms: BMY7378; BMY-7378; 1,1-Cyclopentanediacetimide, N-(2-(4-(o-methoxyphenyl)-1-piperazinyl)ethyl)-, dihydrochloride; N-(2-(4-(o-Methoxyphenyl)-1-piperazinyl)ethyl)-1,1-cyclopentanediacetimide dihydrochloride. Grade: >98%. CAS No. 21102-95-4. Molecular formula: C22H33Cl2N3O3. Mole weight: 458.42. | |
| BMY 7378 | BMY 7378 is a selective antagonist of α1D-adrenoceptor (α1D-AR). BMY 7378 binds to membranes expressing the cloned rat α1D-AR with a >100-fold higher affinity (Ki=2 nM) than binding to either the cloned rat α1A-AR (Ki=800 nM) or the hamster α1B-AR (Ki=600 nM). BMY 7378 is a 5-HT1A receptor partial agonist[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 21102-95-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100554. | |
| BMY 7378 dihydrochloride | BMY 7378 dihydrochloride. Group: Biochemicals. Grades: Purified. CAS No. 21102-95-4. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| BN-227F | BN-227F is an antibiotic produced by Pseudomonas sp. BN-227. It has anti-gram-positive and negative bacteria activity. Synonyms: Antibiotic BN 227F. CAS No. 72907-24-5. Molecular formula: C21H24FeN3O9. Mole weight: 518.27. | |
| BN80933 | BN80933 is a dual inhibitor of lipid peroxidation (IC50 = 0.29 μM) and neuronal nitric oxide synthase (nNOS) (Ki = 0.92 μM). Synonyms: (S)-N-(4-(4-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-carbonyl)piperazin-1-yl)phenyl)thiophene-2-carboximidamide. Grade: 98%. CAS No. 214348-10-4. Molecular formula: C29H34N4O3S. Mole weight: 518.67. | |
| BN 82002 | BN 82002, also known as CDC25 Phosphatase Inhibitor I, is a cell-permeable ortho-hydroxybenzylamino compound that displays anti-tumor properties. Synonyms: BN-82002; BN82002; Phenol, 4-(dimethylamino)-2-methoxy-6-((methyl(2-(4-nitrophenyl)ethyl)amino)methyl)-. CAS No. 396073-89-5. Molecular formula: C19H25N3O4. Mole weight: 359.42. | |
| BN-82685 | BN-82685 is a a quinone-based CDC25 inhibitor with IC50 of 201 nM, 117 nM, 109 nM, 160 nM, 249 nM, for CDC25C, CDC25C-cat, CDC25A, CDC25B2, CDC25B3, respectively. BN-82685 plays an important role in cancer research[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: IRC-083065. CAS No. 477603-18-2. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-121065. | |
| Bn-AFP1 | Bn-AFP1 was found in Brassica napus. It has effects on fungi. | |
| b-Naphthyl-b-maltotrioside | b-Naphthyl-b-maltotrioside is a highly esteemed enzymatic substrate extensively employed in the realm of biomedical science, encompassing a consequential instrument empowering the analysis of lactase insufficiency and enzyme efficacy. Synonyms: Naphthyl O-α-D-glucopyranosyl-(1→4)-O-α-D-glucopyranosyl-(1→4)-β-D-glucopyranoside; Naphthyl β-maltotrioside; (2R,3R,4S,5S,6R)-2-(((2R,3S,4R,5R,6R)-6-(((2R,3S,4R,5R,6S)-4,5-dihydroxy-2-(hydroxymethyl)-6-(naphthalen-2-yloxy)tetrahydro-2H-pyran-3-yl)oxy)-4,5-dihydroxy-2-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol. Molecular formula: C28H38O16. Mole weight: 630.59. | |
| BNC-105 | BNC105 is a novel compound being developed by Bionomics as a Vascular Disrupting Agent (VDA) for treatment of cancer. VDAs are drugs that disrupt the blood vessels that nourish tumours. BNC105 acts as a tubulin polymerization inhibitor and displays 80-fold higher potency against endothelial cells than that of CA4P. CA4P is a VDA currently under evaluation in phase III clinical trials. BNC105 is more potent and offers a wider therapeutic window. CA4P produces 90% vascular disruption at its no observed adverse event level (NOAEL), whereas BNC105 causes 95% vascular disruption at 1/8th of its NOAEL. Tissue distribution analysis of BNC105 in tumor-bearing mice showed that while the drug is cleared from all tissues 24 hours after administration, it is still present at high concentrations within the solid tumor mass. Furthermore, BNC105 treatment causes tumor regressions with complete tumor clearance in 20% of treated animals. Synonyms: BCN-105; BCN105; BCN 105. CAS No. 945771-74-4. Molecular formula: C20H20O7. Mole weight: 372.373. | |
| BNC105P | BNC105P is a benzofuran-based vascular disrupting agent (VDA) prodrug with potential anti-vascular and antineoplastic activities. Upon administration vascular disrupting agent BNC105P, the disodium phosphate ester of BNC105, is rapidly converted to BNC105; in activated endothelial cells, BNC105 binds to tubulin and inhibits its polymerization, which may result in a blockage of mitotic spindle formation, cell cycle arrest, and disruption of the tumor vasculature. Hypoxic conditions ensue, depriving tumor cells of nutrients and resulting in tumor cell apoptosis. In addition to its VDA activity, this agent has a direct cytotoxic effect on tumor cells by inhibiting tubulin polymerization. BNC105 is not a substrate for the multidrug-resistance P-glycoprotein (Pgp) transporter. Check for active clinical trials or closed clinical trials using this agent. Synonyms: BNC105P; BNC 105P; BNC-105P. CAS No. 945771-96-0. Molecular formula: C20H19Na2O10P. Mole weight: 496.32. | |
| BNC375 | BNC375 is a potent, selective, and orally available type I positive allosteric modulator of α7 nAChRs. Synonyms: 4-((1R,3R)-3-(((5-chloro-2-methoxyphenyl)amino)methyl)-2,2-dimethylcyclopropyl)benzenesulfonamide. Grade: 99%. CAS No. 1557240-80-8. Molecular formula: C19H22ClN2O3S. Mole weight: 394.91. | |
| Bn-D-Ser-OH | Bn-D-Ser-OH. Synonyms: D-N-Benzylserine; N-Benzyl-D-serine. CAS No. 106910-77-4. Molecular formula: C10H13NO3. Mole weight: 195.21. | |
| b-Nicotinamide adenine dinucleotide 3'-phosphate sodium salt hydrate | b-Nicotinamide adenine dinucleotide 3'-phosphate sodium salt hydrate, a pivotal coenzyme in the biomedical arena, exhibits its significance as a redox carrier and electron donor in diverse metabolic reactions. With its application in the amelioration of oxidative stress-induced ailments, including cardiovascular diseases and neurological disorders, this product assumes a critical function in cellular energy synthesis and the preservation of cellular well-being. Imbibed with indispensability, it perpetuates the vitality of the biotic system. Molecular formula: C21H27N7O17P3·xNa·yH20. Mole weight: 742.40 (anhydrous free acid). | |
Our database is helping our users find suppliers everyday.
